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Inverse Regulation of Inﬂammation and Mitochondrial
Function in Adipose Tissue Deﬁnes Extreme Insulin
Sensitivity in Morbidly Obese Patients
Mohammed Qatanani,1,2 Yejun Tan,1,3 Radu Dobrin,1,3 Danielle M. Greenawalt,1,3 Guanghui Hu,1,3
Wenqing Zhao,1,3 Jerrold M. Olefsky,4 Dorothy D. Sears,4 Lee M. Kaplan,5 and Daniel M. Kemp1,2
Obesity is associated with insulin resistance, a major risk factor
for type 2 diabetes and cardiovascular disease. However, not all
obese individuals are insulin resistant, which confounds our un-
derstanding of the mechanistic link between these conditions. We
conducted transcriptome analyses on 835 obese subjects with
mean BMI of 48.8, on which we have previously reported genetic
associations of gene expression. Here, we selected ;320 nondi-
abetic (HbA1c,7.0) subjects and further stratiﬁed the cohort into
insulin-resistant versus insulin-sensitive subgroups based on
homeostasis model assessment–insulin resistance. An unsuper-
vised informatics analysis revealed that immune response and
inﬂammation-related genes were signiﬁcantly downregulated
in the omental adipose tissue of obese individuals with extreme
insulin sensitivity and, to a much lesser extent, in subcutaneous
adipose tissue. In contrast, genes related to b-oxidation and the
citric acid cycle were relatively overexpressed in adipose of
insulin-sensitive patients. These observations were veriﬁed by
querying an independent cohort of our published dataset of 37
subjects whose subcutaneous adipose tissue was sampled before
and after treatment with thiazolidinediones. Whereas the immune
response and inﬂammation pathway genes were downregulated
by thiazolidinedione treatment, b-oxidation and citric acid cycle
genes were upregulated. This work highlights the critical role that
omental adipose inﬂammatory pathways might play in the path-
ophysiology of insulin resistance, independent of body weight.
Diabetes 62:855–863, 2013
The number of obese individuals worldwide hasreached two billion, leading to an explosion ofobesity-related health problems associated withincreased morbidity and mortality (1,2). The in-
crease in the prevalence of obesity is strongly correlated
with an increase in type 2 diabetes mellitus, reaching ep-
idemic proportions in the United States (3,4). A key etio-
logical factor linking obesity to type 2 diabetes mellitus is
insulin resistance, characterized by decreased response
in the cellular actions of insulin, leading to an impaired
ability of insulin to inhibit glucose output from the liver
and to promote glucose uptake in fat and muscle (5,6). The
physiological mechanisms connecting obesity to insulin
resistance have received intense investigation in recent
years and several hypotheses have emerged, such as ec-
topic lipid accumulation in liver and muscle secondary to
obesity-associated increase in serum free fatty acids, al-
tered production of various adipocyte-derived factors
(collectively known as adipokines), and low-grade inﬂa-
mmation of white adipose tissue resulting from chronic
activation of the innate immune system (7,8).
The association between obesity and insulin resistance
is likely a cause-and-effect relationship because human
and animal studies indicate that weight loss and weight
gain correlate closely with increasing and decreasing in-
sulin sensitivity, respectively (9–11). However, not all
obese individuals are insulin-resistant. In fact, insulin
sensitivity can vary up to six-fold in this population, which
highlights the importance of identifying genetic and envi-
ronmental factors that place obese individuals at the
greatest risk for obesity-related complications (12–14). It
has been recognized that the adipose tissue, in addition to
its role as an energy storage depot, is a bona ﬁde endo-
crine organ with a key role in controlling whole-body
metabolism (7,15). Adipose tissue actively secretes cyto-
kines and hormones that regulate food intake, glucose
metabolism, and whole-body nutrient homeostasis (16).
The expansion of adipose tissue in obesity is associated
with the activation of chronic proinﬂammatory pathways
and macrophage inﬁltration, which ultimately impairs its
function as an energy depot as well as an endocrine gland
with detrimental consequences for the whole body (7,17–19).
However, despite increasing awareness of the role inﬂa-
med adipose tissue plays in obesity-related insulin re-
sistance, there is limited understanding of the molecular
signals that differentiate insulin-resistant from insulin-
sensitive obese individuals. This is because the majority of
studies in this area have focused on comparisons of lean
and obese individuals, obviating the potential causal fac-
tors of body weight per se on insulin sensitivity (20,21).
These studies, however, could not reveal the gene ex-
pression signature responsible for the metabolically com-
promised status of obese individuals independent of their
weight. A few recent studies of very small cohorts have
been reported that point to a role for adipocyte size and
differentiation potential, as well as to modest increases in
a limited set of inﬂammatory genes in the development of
insulin resistance, independent of obesity (22–27).
Because equally obese individuals can differ dramati-
cally in their overall sensitivity to insulin, we performed a
highly powered transcriptome study of our previously pub-
lished transcription dataset from .800 obese individuals to
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identify the molecular pathways associated with insulin
sensitivity, independent of body mass (28). Speciﬁcally, we
conducted a comprehensive transcription proﬁling analy-
sis on subcutaneous and omental adipose tissue samples
collected from this entire cohort of obese subjects during
bariatric surgery procedures. Our results emphasize the
role of the immune system and mitochondrial function in
the etiology of insulin resistance, independent of obesity.
RESEARCH DESIGN AND METHODS
Roux-en-Y gastric bypass (RYGB) proﬁling study. Omental and subcu-
taneous adipose tissues were collected between 2000 and 2007 from patients
before undergoing gastric bypass surgery at Massachusetts General Hospital.
Demographic data including age, race, and gender for both the entire cohort
and the selected subpopulation in our analysis are shown in Supplementary
Fig. 1. Additional metabolic traits are summarized in Supplementary Fig. 3,
which shows the distribution of BMI, white blood cell (WBC) count, fasting
glucose, HbA1c, log10(Insulin), log10(HOMA-IR), LDL, and triglyceride, as well
as a table summary of the minimum, maximum, median, and 25% and 75%
percentiles for these traits. Samples were collected in RNAlater (Ambion/
Applied Biosystems) stored at 280°C and shipped to Rosetta Inpharmatics
Gene Expression Laboratory, Seattle, Washington, for extraction, ampliﬁ-
cation, labeling, and microarray processing (28). RNA was converted to
ﬂuorescently labeled cRNA that was then hybridized to custom 44 K DNA
oligonucleotide microarrays manufactured by Agilent Technologies as de-
scribed previously (29). Gene expression data were analyzed using Rosetta
Resolver gene expression analysis software (version 7.0; Rosetta Biosoftware,
Seattle, WA) and MATLAB (The MathWorks, Natick, MA). The expression data
are available at GEO super series (Accession ID GSE24335). ANOVA analysis
and Pearson correlation analysis were performed to select gene signatures
that were differentially expressed between high HOMA-IR and low HOMA-IR
subgroups from nondiabetic patients with HbA1c ,7%. Monte Carlo simulation
from a randomly permuted dataset was used to estimate and control the false
discovery rate. In general, the omental and subcutaneous fat samples were
taken from the same individual, but a small portion of fat tissue proﬁles were
missing because of sample quality and array proﬁling quality issues. Table 1
shows the overlapping samples (i.e., samples from the same individual).
Peroxisome proliferator–activated receptor g drug treatment proﬁling
study. Microarray data from a previously published study (30) were analyzed
using the tools described. Adipose tissue biopsies were performed in normal
lean subjects, obese insulin-resistant nondiabetic subjects, and obese insulin-
resistant type 2 diabetic subjects (n = 8, 9, and 20, respectively) before and
after 3-month treatment with either pioglitazone or rosiglitazone. RNA from
the adipose tissue samples was proﬁled on Affymetrix Human Genome U133
Plus 2.0 Arrays. The array contains a total of 54,675 probe sets. A total of 74
arrays were available and used for the analysis. The dataset includes 38 pro-
ﬁles obtained from 19 subjects before and after pioglitazone treatment, and 36
proﬁles obtained from 18 subjects before and after rosiglitazone treatment.
The log ratio of gene expression is calculated by subtracting the log intensity
of baseline study from the log intensity of the compound treatment.
National Health and Nutrition Examination Survey data analysis. Na-
tional Health and Nutrition Examination Survey III Survey data were down-
loaded from the Centers for Disease Control and Prevention website http://
www.cdc.gov/nchs/nhanes.htm. This survey includes .31,311 subjects and
was conducted from 1988 to 1994. BMI data for subjects older than 20 years
were extracted and plotted along with BMI data obtained from the obese
subjects in the RYGB proﬁling study. HOMA-IR was calculated as fasting
plasma glucose multiplied by fasting plasma insulin, with the units [(mg/dL)3
(mU/mL)]/405, according to the protocol described previously (31).
Pathway enrichment analysis. Enrichment of GO Biological Process terms in
the annotation of sets of probes was tested using Gene Set Annotator in the
Merck Target and Gene Information (TGI) System, which provides pathway
enrichment analysis to ﬁnds gene sets in which a user-supplied set of identiﬁers
is signiﬁcantly enriched. The P value was calculated using the hypergeometric
distribution, and the E value was calculated using the Bonferroni adjusted P
value. Top 20 signiﬁcantly enriched pathways with E value ,0.005 were listed
for the selected omental tissue signature genes; for the side-by-side compari-
son purpose, top 20 pathways ranked by E value also were listed for the se-
lected subcutaneous tissue signature genes. Gene overlap was based on
human database identiﬁcation numbers. The allowed maximum and minimum
gene set sizes for the pathway terms were 500 and 5, respectively.
Method and statistical algorithm used to select signiﬁcantly
differentially expressed genes in low and HOMA-IR analysis. Within non-
diabetic patients and patients not using medicine, we selected subjects with
HbA1c #7. The following steps were taken. For step 1, subjects were ranked
by HOMA-IR trait, then ANOVA was conducted (parametric) and Kruskal-
Wallis (nonparametric) analyses were performed to select genes that were
differentially expressed between the top 10% and bottom 10% of patient
groups. Then, we identiﬁed the intersect genes that have P#0.01 in both
ANOVA and Kruskal-Wallis analyses. For step 2, we repeated step 1 for the top
15% and bottom 15% of patient groups. For step 3, we repeated step 1 for the
top 20% and bottom 20% of patient groups. For step 4, we performed a union of
the selected genes from steps 1–3. For step 5, we conducted Pearson (para-
metric) and Spearman (nonparametric) correlation analyses between the log
ratio data of gene expression and log10 (HOMA-IR) trait, and selected genes
that have correlation P#0.01 in both Pearson and Spearman analyses. For step
6, we intersected selected genes between steps 4 and 5. The resulting differ-
entially expressed genes for HOMA-IR trait in omental and subcutaneous tis-
sues were 968 and 546, respectively. For step 7, we conducted Monte Carlo
simulation, randomly permuted HOMA-IR trait, and then repeated steps 1–6 to
determine the number of selected false-positive genes using the same statisti-
cal approaches. Finally, for step 8, we repeated step 7 250 times using the
median of the number of selected false-positive genes to calculate the false
discovery rate.
The numbers of false-positive genes selected by the described Monte Carlo
process from the omental and subcutaneous tissue proﬁles were 94 and 68,
respectively; therefore, the false discovery rates for these high and low HOMA-
IR gene selections were 9.7% and 12.5% for the omental and subcutaneous
tissues, respectively.
We used the Rosetta custom Agilent 44 K array. The array contains multiple
probes for some genes. In the gene selection step, we treated each probe in-
dependently and did not intend to combine different probes for the same gene
because we believed that different probe design for the same gene constitutes
a systemic, instead of random, bias in detecting the gene expression level. Only
in the pathway analysis step did we combinemultiple probes for the same genes
and we counted the gene only once in the enrichment test.
Algorithm of unsupervised clustering. We used the hierarchical agglom-
erative clustering for the algorithm of unsupervised clustering ﬁgure. The basic
algorithm was performed as follows: 1) we computed the distance matrix of
the genes by using log10 ratio data, and we computed the similarity function of
1 2 cosine correlation; 2) we amalgamated the data in the distance matrix by
fusing a gene or groups of genes that were most similar, and the average link
was used to calculate the distance from a cluster to all remaining unclustered
points; and 3) we computed the dendrogram (returning a tree structure). The
tree is a top-down collection of tree nodes such that the root node has a dis-
tance of 0.0. We believe that this unsupervised clustering algorithm is ideal to
build a cluster hierarchy among the hidden data structure, and thus reveal the
patterns of coexpression among selected signature genes.
RESULTS
A total of 835 omental and 697 subcutaneous fat samples
were proﬁled using whole-genome microarrays to deter-
mine gene transcription levels in samples from obese in-
dividuals undergoing bariatric surgery. To test hypotheses
regarding insulin sensitivity in this obese cohort, we ex-
cluded those patients with type 2 diabetes mellitus, as
deﬁned by their physician’s diagnosis, those with plasma
HbA1c levels .7.0, or those who were using diabetes me-
dication. We also excluded patients using long-term med-
ications such as statins to minimize pharmacological
effects on gene expression. As a result of this ﬁltering
process, the ﬁnal sample set consisted of 387 omental and
323 subcutaneous fat expression proﬁles (Table 1). The
distribution of the BMI of the studied cohort compared
with the BMI of National Health and Nutrition Examina-
tion Survey III survey is shown in Fig. 1A. In general,
TABLE 1
Patient pool samples used in this study
Total patient
samples Nondiabetic
Nondiabetic and
no medicine
Omental 835 463 387
Subcutaneous 697 379 323
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a wide distribution of HOMA-IR and HbA1c was observed
across the entire cohort, as shown in Fig. 1B, and partic-
ularly within the nondiabetic subgroup not using medica-
tion there was a broad range of HOMA-IR, highlighting the
existence of both extremely insulin-sensitive and insulin-
resistant obese individuals. Therefore, we aimed to deter-
mine whether gene expression patterns could be identiﬁed
that correlate with the profound variability in insulin sen-
sitivity in obese individuals, independent of BMI.
We conducted correlation analyses in the nondiabetic
nonmedicated subgroup to identify genes displaying sig-
niﬁcant association with HOMA-IR. In addition, we con-
ducted ANOVA analyses in which we selected the top and
bottom 15 percentiles based on HOMA-IR and directly
compared these two groups for differentiated expression
patterns (Fig. 1C, D). It is worth noting that the HOMA-IR
of the bottom 15 percentile in our obese insulin-sensitive
subpopulation is similar to the HOMA-IR in a lean nondia-
betic general population cohort (HOMA-IR, 2.8; interquartile
range, 1.55) (32). The heat maps revealed hierarchical
clustering and signiﬁcant differentiation in gene expres-
sion across the HOMA-IR spectrum in both subcutaneous
tissue and omental tissue, implicating both adipose depots
as key phenotypic effectors of insulin sensitivity in obese
individuals. Next, we conducted pathway enrichment an-
alyses comprising the subgroup signiﬁcantly associated
with insulin sensitivity in omental (968 genes) and sub-
cutaneous (546 genes) tissue samples. Description of these
genes is presented in Supplementary Table 1. The rank
order of pathways that were most signiﬁcantly repre-
sented by the differential gene expression data are listed
in Table 2. In omental tissue, inﬂammatory and immune-
related pathway annotations were highly enriched in the
gene set that showed signiﬁcant regulation between ex-
tremes of insulin sensitivity. In contrast, in subcutaneous
fat, we did not identify any signiﬁcant pathway enrichment
based on the 546 differentially expressed genes. Correla-
tion analysis of HOMA-IR and the demographic traits,
including age, race, and gender, showed no signiﬁcant
correlation (Supplementary Fig. 2). We realize that the
lack of correlation between these factors and HOMA-IR
does not preclude a correlation in expression of some
HOMA-IR correlated transcripts. Hence, to strengthen our
analysis, our gene expression data have been normalized
by multiple steps, including the gender, age, and ethnic
groups as described (28).
Progression from the unsupervised analysis to a semi-
supervised approach enabled better resolution of the role
of inﬂammatory and immune pathway regulation in adi-
pose tissue with respect to whole-body insulin sensitivity.
A set of 191 unique genes (270 probes) that have been
associated with immune function were obtained from In-
genuity (Ingenuity Systems, www.ingenuity.com) and were
examined by comparing relative gene expression levels in
omental or subcutaneous fat between those individuals
with high HOMA-IR and those with low HOMA-IR. In
querying this integrated gene set, it was clear that the
immune response pathway was downregulated in both
fat depots of insulin-sensitive compared with insulin-
resistant obese individuals, but that the signal was signif-
icantly more associated with insulin sensitivity in the
omental versus subcutaneous fat (Fig. 2A). To better-qualify
this observation, we leveraged a second gene expression
data set from a separate cohort that provided relative gene
transcription levels in subcutaneous fat from individuals
who had undergone thiazoladinedione (TZD) treatment
for 3 months (30). TZDs are a class of insulin-sensitizer
drug that have been shown to robustly improve HOMA-IR
in humans (33). As expected, the immune response sig-
nature showed an overall reduction in expression level,
consistent with the inverse response observed in the in-
sulin resistant state. When broken-down to individual genes,
the immune response gene set showed a highly signiﬁcant
inverse correlation between the two cohorts, consistent
with the directionality of HOMA-IR response in these
separate studies (parametric Pearson correlation; corre-
lation degree, 20.60071; P = 6.4e-20) (Fig. 2B). This degree
of negative correlation at the level of individual genes in-
dicated that immune response was oppositely regulated
between insulin-resistant patients with high HOMA-IR
level and subjects with improved insulin sensitivity after
TZD treatment, further validating the observation that the
majority of known immune genes were highly associated
with the level of insulin resistance.
Elevated WBC count is a marker of inﬂammation and
has been reported to associate with insulin resistance and
development of type 2 diabetes mellitus (34). We assessed
whether speciﬁc adipose depots expressed an association
between WBC levels and expression of genes known to be
involved in immune response. Shown in Fig. 2C are nor-
malized distribution charts for the correlation coefﬁcients
between expression of the known immune genes and WBC
count. In omental tissue, 225 out of 270 probes for the
known immune genes had a positive correlation with the
WBC count, whereas 45 out of 270 probes had a negative
correlation. The P value for this uneven distribution from
the sign test was 1e227, indicating that the majority of the
known immune genes were associated with the high WBC
in obese individuals with elevated HOMA-IR. In subcu-
taneous tissue, 185 out of 270 probes had a positive cor-
relation with the WBC and 85 out of 270 probes had
a negative correlation, and the degree of unevenness was
signiﬁcant with P = 1e29. In conclusion, the majority of the
known immune genes in both omental and subcutaneous
tissues were overexpressed and positively associated with
WBC count, although the degree of association between
gene expression and WBC counts was much stronger in
omental tissue than in subcutaneous tissue. However, we
observed little correlation between WBC and HOMA-IR
traits among the entire cohort in this dataset (Supple-
mentary Fig. 4). This highlights the complex relationships
among WBC counts, HOMA-IR, and immune genes, and
supports the possibility that the changes in gene expres-
sion are not a reﬂection of changes in cell number but are
more likely a reﬂection of changes in gene expression
within each cell.
Finally, we deﬁned small gene sets that relate to speciﬁc
cell functions or cell phenotypes involved in the adipose
inﬂammation response triggered by obesity (35). These
subcellular signatures then were examined for association
with insulin sensitivity. Notably, signatures related to mac-
rophage cells were clearly upregulated as a function of
high HOMA-IR, whereas there was no clear trend observed
in mast cell signatures in the omental or subcutaneous
adipose depots, but T-cell signatures were upregulated
mainly in the omental depot (Fig. 3A). Concordantly, the
macrophage signatures trended in the opposite direction
in subcutaneous adipose tissue from subjects treated with
TZDs, consistent with improved insulin sensitivity and
lower HOMA-IR. Gene sets related to mitochondrial func-
tions of b-oxidation and the tricarboxylic acid (TCA) cycle
were of speciﬁc interest with respect to implications of
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FIG. 1. A: The BMI distribution curve (magenta) for patients who were involved in the RYGB proﬁling experiments, and the BMI distribution curve
(gray) for the general population in National Health and Nutrition Examination Survey (NHANES) III survey. B: A dot plot comparing HOMA-IR
trait vs. HbA1c trait for the patients who were involved in our proﬁling studies (nondiabetic, did not use any medicine, and had HbA1c <7%; gray).
The red dots represent patients who had higher HOMA-IR level (top 15%), the blue dots represent patients who had lower HOMA-IR level (bottom
15%) among the patients included in the proﬁling analysis. C: A heat map showing the one-dimensional histogram of the 968 selected omental
genes that differentiate between high and low HOMA-IR levels in the unsupervised analysis. Magenta in the heat map indicates upregulation and
cyan indicates downregulation for the individual patient sample compared with the pool of all patient samples. D: A heat map showing the
one-dimensional histogram of the 546 selected subcutaneous genes that differentiate between high and low HOMA-IR levels in the unsupervised
analysis. The methodology used for calculating the algorithms for unsupervised clustering can be found in the Supplementary Materials. (A high-
quality digital representation of this ﬁgure is available in the online issue.)
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metabolic status of adipose tissue on insulin sensitivity. In
both omental and subcutaneous fat samples, there was
a clear trend toward upregulation of mitochondrial func-
tion in individuals with low HOMA-IR, and the same trend
was observed in individuals after treatment with TZDs.
These data indicate that insulin sensitivity associates with
increased levels of cellular metabolism in adipose tissue
in obese individuals and suggest that increased mito-
chondrial function in adipocytes, along with reduced mac-
rophage levels in fat depots, is tightly associated with
improved insulin sensitivity. This potential link was further
supported by distribution plots that revealed a positive
correlation of inﬂammatory genes with WBC count and
a signiﬁcantly negative correlation of mitochondrial gene
expression with WBC count (Fig. 3B). The fact that we did
not identify the genes in mitochondrial function in our
pathway analysis in Supplementary Table 1 might highlight
one of the intrinsic limitations in the methodologies used
in pathway analysis. These pathway methodologies do not
allow differentiation of each pathway based on individual
genes in the pathway (i.e., treatment of all genes equally
without regard to how important each gene is in a partic-
ular pathway or where it is on the hierarchy). Moreover,
pathway analysis depends on certain genes in a pathway
and not on the magnitude of change in gene expression
within that pathway. This is the reason we decided to use
a combination of unsupervised, semisupervised, and tar-
geted analyses in our analysis to better reveal the important
relationships between inﬂammation and mitochondrial
function and insulin resistance.
DISCUSSION
Our ﬁndings demonstrate that inﬂammation of omental
adipose tissue is strongly associated with insulin resis-
tance, in the context of obesity, in a morbidly obese pop-
ulation. In contrast to the upregulation of the inﬂammation
signature, genes related to b-oxidation and the citric acid
cycle were underexpressed in the insulin-resistant state.
In a separate population, these gene expression changes
were reversed after TZD treatment, implicating these
pathways in the mechanism of action for these insulin-
sensitizing antidiabetic drugs. Our ﬁndings are consistent
with a recently published report showing an increase in
TCA cycle and b-oxidation gene signatures and a decrease
in inﬂammation signatures correlating with insulin sensi-
tivity before and after TZD treatments, which adds further
validation to our ﬁndings (30).
Obesity is now recognized as a state of chronic low-
grade systemic inﬂammation that may play a role in the
development of insulin resistance with a central role for
adipose tissue macrophages (18,19,36). Here, we conﬁrm
that macrophage gene signature is upregulated in the
insulin-resistant state. Interestingly, signatures of both pro-
inﬂammatory M1 as well as anti-inﬂammatory M2 macro-
phages are upregulated in contrast to what has been
TABLE 2
Listing of the top-ranked GO Biological Process terms from the enrichment analysis of the selected 968 omental genes and for the 546
selected subcutaneous genes
Omental (gene 968) Subcutaneous (gene 546)
Enriched pathways E value
Rank in
subcutaneous Enriched pathways E value
Rank in
omental
Immune response 3.27E-09 1,161 Regulation of angiogenesis 0.718 942
Defense response 9.64E-07 438 Microtubule-based process 0.98 2406
Response to external
stimulus 1.08E-06 1,524 Cell cycle 0.989 2,684
Regulation of immune
system process 3.61E-06 1,195 Mitotic sister chromatid segregation 0.993 .2,937
Cell activation 3.90E-05 1,630 Microtubule cytoskeleton organization 0.994 2,551
Regulation of immune
response 5.01E-05 253 Sister chromatid segregation 0.996 .2,937
Response to biotic stimulus 5.80E-05 1,163 Regulation of anatomical structure
morphogenesis 0.997 1,202
Response to other organism 7.97E-05 1,006 Regulation of cell cycle 1 2,299
Regulation of signaling
process 1.85E-04 62 Mitotic cell cycle 1 2,702
Regulation of response to
stimulus 2.94E-04 50 Cell division 1 2,324
Immune effector process 3.17E-04 774 Cell-cycle phase 1 2,824
Cytokine production 5.50E-04 923 Regulation of mitotic cell cycle 1 1,455
Response to wounding 6.90E-04 398 Glomerular basement membrane
development 1 .2,937
Regulation of transport 7.15E-04 962 Cellular chloride ion homeostasis 1 .2,937
Myeloid leukocyte activation 0.001 1,815 Attachment of spindle microtubules to
kinetochore during mitosis 1 .2,937
Actin ﬁlament organization 0.002 1,905 Chromosome movement toward spindle pole 1 .2,937
Leukocyte activation 0.002 1,564 Chloride ion homeostasis 1 .2,937
Inﬂammatory response 0.002 324 Chromosome segregation 1 2,630
Actin cytoskeleton organization 0.003 1,459 Cell junction organization 1 2,797
Activation of immune response 0.004 1,597 Retinoid metabolic process 1 .2,937
Bonferroni adjusted P values from the hypergeometric tests are shown.
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FIG. 2. A: Heat map showing the expression of the known immune function genes in the omental and subcutaneous tissues of patients with high vs.
low HOMA-IR levels in the RYGB proﬁling experiments and in the subcutaneous tissues of a different cohort of diabetic and nondiabetic subjects
who received pioglitazone and rosiglitazone treatments in the peroxisome proliferator–activated receptor g (PPARg) proﬁling experiment. The
data shown are the average of log10 of the ratio of gene expression between the high HOMA-IR patient group and the low HOMA-IR patient group
for RYGB cohort, and the average of log10 of the ratio of gene expression for patients receiving PPARg treatments and without PPARg treatment
for the PPARg study cohort. B: Dot plot analysis showing the comparison of correlation coefﬁcients between gene expression and HOMA-IR level
in the RYGB proﬁling experiments vs. the correlation coefﬁcients between gene expression and HOMA-IR level in the PPARg proﬁling experiment
for the known immune function genes. The magenta line is the least-squares ﬁtted line for the comparison dot plot. C: Bar charts showing the
evenness of the distribution of correlation coefﬁcients for the expression of immune genes and WBCs in omental tissue (left, green) and in
subcutaneous tissue (right, blue). The number of genes in each bin in the raw histogram is divided by the total number of genes in all bins to give
the normalized histogram. The red curves are the distribution of correlation coefﬁcients for all 44 K array genes with WBCs. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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observed in animal studies (37). Moreover, gene signa-
tures of T cells were upregulated with no difference in
mast cell signature (38,39). It is not clear whether the
difference in the inﬂammatory signature proﬁle is attrib-
utable to changes in gene expression or attributable to a
difference in immune cell recruitment to the adipose tis-
sue, which will be the subject of a future study. Moreover,
the divergence in the gene signature changes between
pioglitazone and rosiglitazone, particularly in the genes
representing the TCA cycle, is worth noting. This cannot
be explained completely by the fact that that pioglitazone
is a weaker peroxisome proliferator–activated receptor
g agonist, given that this phenomenon is not obvious in
the other gene signatures (40). Deeper analysis of these
differences might help us understand the triggers for the
adverse events associated with the different TZD treat-
ments.
It is difﬁcult to determine a causal relationship between
adipose tissue inﬂammation and insulin resistance from
the current study. However, it is known that higher total
leukocyte counts precede and predict the incident risk of
type 2 diabetes mellitus (34). More recently, studies have
shown that insulin resistance in mice with differential
susceptibility to diabetes is preceded by differences in the
FIG. 3. A: Heat map showing the expression of the literature-curated inﬂammation and mitochondrial function genes in the RYGB and peroxisome
proliferator–activated receptor g (PPARg) proﬁling experiments. As in Fig. 2, the data shown are the average of log10 of the ratio of gene ex-
pression between the high HOMA-IR patient group and the low HOMA-IR patient group for RYGB cohort, and the average of log10 of the ratio of
gene expression for patients receiving PPARg treatments and those without PPARg treatment for the PPARg study cohort. B: Bar charts showing
the evenness of the distribution of correlation coefﬁcients for the relationships between expression of inﬂammation genes (left) and WBC count,
and for the relationships between expression of mitochondrial function genes (right) and WBC count. The number of genes in each bin in the raw
histogram is divided by the total number of genes in all bins to give the normalized histogram. The red curves are the distribution of correlation
coefﬁcients for the relationships between expression of all 44 K array genes and WBC count. (A high-quality digital representation of this ﬁgure is
available in the online issue.)
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inﬂammatory response of adipose tissue, emphasizing the
notion that inﬂammation of adipose tissue might play
a role in the etiology of insulin resistance independent of
body weight (41). This suggests that targeting inﬂamma-
tory pathways might prevent the development of insulin
resistance and diabetes. A recent study shows that patients
using anti-inﬂammatory drugs against rheumatoid arthritis
or psoriasis had a signiﬁcantly lower risk of development
of diabetes (42). Rodent models also have shown that diet-
induced insulin resistance is blunted when adipose tissue
inﬂammation is blocked (36,43). Our data implicate a
stronger role for visceral fat inﬂammation versus sub-
cutaneous fat inﬂammation in the etiology of insulin re-
sistance, which is consistent with studies that show that
these adipose tissue depots have unique inﬂammatory
patterns, and which supports the notion that the omental
depot is a stronger contributor to insulin resistance (44).
Finally, several studies have suggested that depot-speciﬁc
adipocyte size may be linked to inﬂammation and can be
a major factor driving insulin resistance (22,25,45,46). In-
creased adipocyte size of omental adipose tissue was as-
sociated with insulin resistance and, among moderately
obese individuals, an increased proportion of small adi-
pose cells is associated with inﬂammation in subcutaneous
adipose tissue, which may reﬂect impaired adipogenesis
or terminal differentiation (22,25). The latter notion was
elegantly demonstrated in a recent article that shows
that genetic predisposition for type 2 diabetes mellitus,
but not obesity, is associated with an impaired ability to
recruit new adipose cells to store excess lipids in the
subcutaneous adipose tissue, thereby promoting ectopic
lipid deposition (47). Studying the relationship among in-
sulin resistance, inﬂammation, and adipocyte size in the
obese subjects in our study will help highlight the inter-
play among these factors and will be the topic of future
studies.
The results of our study highlight a different subpopu-
lation of obese individuals who display an inﬂammatory
signature in their omental adipose tissue, which might
contribute to their state of insulin resistance. It is possible
that individuals with higher basal inﬂammatory signature,
before becoming obese, are more at risk for develop-
ment of insulin resistance, diabetes, and other metabolic
diseases. Understanding the mechanisms and pathways
that lead to these differences will equip us with impor-
tant targets to help stem the tide of such a debilitating
disease.
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